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Primary surgical prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) is the most 
effective option and gold standard for ovarian cancer (OC) risk-reduction, particularly given the 
absence of an effective national OC screening programme. However, premenopausal RRSO leads to 
premature surgical menopause with detrimental long-term health sequelae particularly in women 
who do not/are unable to take hormone replacement therapy (HRT). HRT uptake in women 
undergoing pre-menopausal oophorectomy appears low and is dependent on informed counselling, 
on the safety of HRT and efficacy in mitigating the health sequelae of premature menopause. 
Acceptance of a central role for the fallopian tube in OC etiopathogenesis coupled with detrimental 
consequences of premature menopause, has led to the attractive proposal of early-salpingectomy 
with delayed oophorectomy as an alternative OC surgical prevention strategy in premenopausal 
women who have completed their family but decline or wish to delay RRSO. The successful 
implementation of risk reducing surgery for OC prevention depends on acceptability of surgery to 
both recipients (e.g. BRCA1/BRCA2 carriers) and intervention deliverers (healthcare 
professionals/researchers). Acceptability is also informed by an understanding of health outcomes 
following risk reducing surgery and the safety of HRT.  It is therefore vital to understand the effects 
of surgery on important health outcomes such as cardiovascular health, neurological function and 
bone health. We present a comprehensive review of acceptability, selected health outcomes above 
and HRT safety following risk reducing surgery. 
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Targeted surgical prevention of ovarian cancer 
BRCA1/BRCA2 carriers have a ~17%-44% risk of ovarian cancer (OC) and ~65-72% risk of breast 
cancer (BC).
1-4
 Primary surgical prevention in the form of risk-reducing salpingo-oophorectomy 
(RRSO) is the most effective option and gold standard for OC risk-reduction, particularly given the 
absence of an effective national OC screening programme. Premenopausal RRSO leads to premature 
surgical menopause which has detrimental long-term health sequelae (increased risk of heart 
disease, osteoporosis, vasomotor symptoms, sexual dysfunction, neurocognitive decline) especially if 
unable to use hormone-replacement-therapy (HRT) due to a personal history of BC.
5-13
 RRSO is 
typically offered from ages 35–40 years for BRCA1-carriers and 40–45 years for BRCA2-carriers. 
Decision making is affected by numerous factors. It is a complex and dynamic process and timing 
needs to be individualised following informed counselling. Much of the literature used to counsel 
high risk women on the effects of oophorectomy on cardiovascular health, bone health and 
neurological function is derived from the low risk population. There are many misperceptions on the 
safety of HRT use in BRCA carriers and the counselling received by patients from clinicians is known 
to be inconsistent. 
 
Acceptance of a central role for the fallopian tube in OC etiopathogenesis coupled with detrimental 
consequences of premature menopause, has led to risk-reducing early-salpingectomy and delayed 
oophorectomy (RRESDO) as an attractive two-step alternative OC surgical-prevention strategy in 
pre-menopausal women who have completed their family but decline or wish to delay RRSO. 
RRESDO provides some level of risk-reduction whilst conserving ovarian function and avoiding 
negative health effects of premature menopause. Lack of clarity on several key issues supports 
offering RRESDO solely within a research setting. Extent of OC-risk reduction and long-term health 
outcomes with early-salpingectomy including on ovarian-function/premature-menopause remain 
4 
 
unclear. Salpingectomy will not prevent OC arising outside the fallopian tube. Residual fimbrial tissue 
implants on the ovarian surface after salpingectomy are reported in 9.8% cases,
14
  and could become 
a potential site for malignant transformation. Etiopathogenesis of OC is complex and our current 
understanding incomplete. Serous-tubular-intraepithelial-carcinoma (STIC) has been described but 
the natural history, progression-rates, outcomes and rate-limiting step in development of OC 
associated with different types is unknown.
15
 STICs may not be precursors to all HGSOC cases.
16
 
Concerns exist regarding attrition from delayed-oophorectomy. A proportion who miss delayed-
oophorectomy may develop OC. Uncertainties remain around cost-effectiveness. There is also the 
potential for increased morbidity resulting from two surgeries instead of one. 
 
Acceptability and its importance 
Successful implementation of risk-reducing surgery for OC-prevention depends on acceptability of 
surgery to both recipients (BRCA1/BRCA2-carriers) and intervention deliverers (healthcare 
professionals/researchers).
17, 18
 If it is considered acceptable, BRCA1/BRCA2-carriers are more likely 
to adhere to recommendations and benefit from improved clinical-outcomes. From the healthcare 
professionals perspective, if delivery of risk-reducing surgery to BRCA1/BRCA2-carriers has low 
acceptability, surgery may not be delivered as intended (by intervention designers), impacting 
overall effectiveness of the strategy. The references to ‘acceptability’ in UK Medical-Research-
Council (MRC) guidance documents on appropriate methods for designing and evaluating complex 
interventions
19-21
 has increased over the years reflecting its growing importance in healthcare, rising 
from nil in 2000 to fourteen-times in 2015. For the purpose of this review we have measured 




We conducted a systematic review on acceptability of ‘risk reducing surgery’, the effects of surgery 
on cardiovascular/bone/neurological health and the safety of HRT in BRCA1/BRCA2 carriers to aid 




Search-strategy and selection-criteria 
Five databases were searched from inception to January-2019 using a common search-strategy 
(supplementary-table-1): Pubmed, Medline, Embase, CINAHL and PsycINFO.  Additionally we 
searched web-based platforms including specialised journals, Google-searches for grey-literature, 
conference-proceedings and clinical-trial registries (ISRCTN-registry/ClinicalTrials.gov registry). 
Searches were not restricted by geographical location, publication-year or study-design, but limited 
to human studies and English-language. The search was re-run prior to final analyses to capture 
recently published studies. 
 
Reference-lists of publications retrieved were screened and transferred into reference-management 
software (EndNote-X8.2, Clarivate-Analytics). Titles/abstracts were screened followed by retrieval 
and screening of full-text articles fulfilling eligibility-criteria.  
 
Predefined inclusion-criteria were BRCA1/BRCA2-carriers undergoing RRSO or RRESDO. Outcome-
measures were: uptake; cardiovascular health; bone health; neurological health; HRT-uptake, safety 
and efficacy (in alleviating the health consequences of premature menopausae). 
 
Exclusions included abstracts/studies that included participants with a personal history of OC, 




Data-extraction, Quality-assessment and Analysis 
Data were extracted using a standardised, predesigned formatted-sheet (following piloting and 
refinement) in Microsoft-Excel 2013. Four main categories of data were extracted: methodological 
characteristics, study-population, surgical-interventions (RRSO/RRESDO), reported outcome-
measures. Risk of bias was assessed using the MINORS (Methodological-Index for Non-Randomized-
Studies) checklist. Higher scores indicated greater quality studies. No studies were excluded from 
data synthesis based on quality-assessment scores. We tabulated characteristics and reported 
outcome-measures of all studies for qualitative synthesis. 
 
RESULTS AND COMMENTARY 
Supplementary-figure-1 provides the flow-chart outlining search outcomes and the study-selection 
process. Searches of electronic databases and reference-lists generated 3547 references. On 
evaluation of titles and abstracts, 612 articles were potentially eligible for detailed assessment, and 
67 met our inclusion-criteria for qualitative-synthesis.  Tables 1-3 summarise relevant-studies. 
 
Uptake of surgery  
Forty-one studies report on uptake of risk-reducing surgery for OC-prevention in BRCA1/BRCA2 
carriers (Table-1). 39/41
22-60
 investigate RRSO uptake and 2/41 RRESDO
61, 62
 uptake. Intention to 
undergo RRSO before BRCA carrier status confirmed (putative uptake) ranges from 16-94%
45, 55, 57
 
and actual uptake (following confirmation of BRCA carrier status) ranges from 12-78%.
34-42, 44-49, 51-59, 
61-68
 RRSO uptake is higher amongst Caucasian population,
39
 BRCA1 (vs BRCA2) carriers,
38, 43, 54, 63, 64
 
older women
38, 45, 63, 68
 and women with a personal history of BC.
35, 68, 69







 Both similar and lower surgical prevention rates for RRSO (and risk 
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reducing mastectomy (RRM)) have been reported in Jewish women, while one study even reports 
higher RRSO rates (54% v 41%, respectively).
28, 41
 It is well recorded that black and minority ethnic 
(BME) populations experience barriers to accessing healthcare.
70
 The same appears to be true 
amongst BME BRCA carriers accessing RRSO. In Cragun et al, uptake of RRSO amongst black and 
Caucasian women was found to be 28% and 77% respectively.
39
 The slightly higher overall RRSO 
uptake observed in BRCA1 (42-76%) than BRCA2-carriers (28-70%)
32, 38, 43, 54, 63, 64
 may be due to the 
higher lifetime-risk of OC with BRCA1. Higher uptake amongst older BRCA-carriers
38, 45, 63, 68
 suggests 
that despite OC-risk, many women prefer to delay RRSO until after completing childbearing),
71
 the 
preference of some to delay this till after menopause and the impact of age on risk. 44-72% BRCA-
carriers undergoing RRSO have a personal history of BC. 
35, 68, 69
 The positive association of history of 
BC with RRSO uptake may be linked to earlier reports of reduction in contralateral BC-risk
72, 73
 
(although recent literature does not support this)
74, 75
 and reduction in BC-specific mortality,
75-78
 
diagnosis of BRCA-status following BC, along with personal preferences.  
 
In contrast to earlier reports suggesting BRCA-carriers undergo surgery within 12-months of their 
BRCA-result,
51
 three time-to-event analyses now show that RRSO-uptake is dynamic and increases 
with time continuing months/years after initial ascertainment/BRCA-diagnosis. 24-38% of BRCA-
carriers undergo surgery >12months after their initial counselling appointment following results of 
genetic-testing.
34, 37, 68
  Unfortunately, most studies (18/32) do not report mean time from 
ascertainment of BRCA-status to RRSO making it difficult to determine the impact on uptake of RRSO 
at different time-points or the impact of publication of international RRSO guidelines or key 





Three longitudinal studies measuring both putative and actual uptake,
45, 55, 57
 show actual uptake is 
lower than putative uptake. Reasons for this discrepancy in uptake were not properly explored. 
 
A pilot prospective, multicentre, non-randomised US study investigating acceptability, surgical 
outcomes, QoL and psychosocial outcomes of RRESDO as an alternative to RRSO or OC screening, 
has reported RRESDO uptake as 44% (19/43) and RRSO uptake as 28% (12/43).
61
 It is possible that 
offering pre-menopausal women who have completed their family RRESDO could reduce uptake of 
pre-menopausal RRSO but may increase the overall number of women undergoing pre-menopausal 
OC surgical prevention as it offers an alternative option to individuals otherwise declining 
oophorectomy due to the negative consequences of premature menopause. 
 
Bone health  
Reported incidence of osteoporosis and osteopenia diagnosed on DEXA scans in BRCA carriers 
following RRSO (both pre and post-menopausal) is 8-14% and 23-57% respectively (table-2).
6, 65, 79-82
 
Pre-menopausal RRSO in BRCA carriers using E-HRT (oestrogen-HRT) is not associated with an 
increased risk of osteoporosis/osteopenia. Challberg et al in a retrospective cohort study, found the 
incidence of osteoporosis and osteopenia to be higher in BRCA carriers with no E-HRT use after pre-
menopausal RRSO in comparison to women who took E-HRT (osteoporosis: 13% vs 3%, osteopenia: 
33% vs 13%).
83
 In a Dutch prospective cohort study, bone mass density (BMD) was not found to be 
lower in BRCA carriers undergoing RRSO (pre and post-menopausal) in comparison to an age-
matched reference population who had not undergone oophorectomy.
6
 However 47% of carriers 
had a history of E-HRT use and this was not adjusted for in the analysis.
6
 Although a prospective 
cohort study by Cohen et al, evaluated differences between the incidence of 
osteoporosis/osteopenia in BRCA carriers undergoing pre or post-menopausal RRSO, the numbers in 
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the analysis (n=30) are too small to draw any meaningful conclusion.
80
 Overall reported outcomes 
are in line with findings that E-HRT preserves BMD.  Evidence from general population studies show 
that BMD declines at a significantly greater rate following oophorectomy (trabecular bone loss from 
the spine 12-19% in the first year) than women who undergo natural menopause (2.5% in the first 
year).
84
 This BMD loss appears to slow down in women using E-HRT following pre-menopausal 
oophorectomy. 
 
Atraumatic fracture risk post RRSO is 4%.
65
 In a prospective cohort  study, RRSO in BRCA carriers was 
not found to be associated with an increased risk of atraumatic fracture and this has also been found 
to be the case in the prospective, observational Nurses’ Health Study of 29,380 women at 
population level risk of OC followed up for twenty-four years.
6, 85
 However a prospective Dutch 
cohort study found a significant increase in bone turnover markers (BTMs): osteocalcin, procollagen 
type-I N-terminal peptide and serum C-telopeptide of type-I collagen, which have been linked to 
future fracture risk, at >2 years after RRSO, in BRCA carriers aged <50 years compared to carriers 
>50.
7
 However, BTMs have limited clinical utility.
86
 It is not routinely recommended to use BTMs to 




Cardiovascular health  
The majority of data pertaining to cardiovascular health following oophorectomy are derived from 
the low risk population and are used to counsel premenopausal high risk women considering RRSO.  
Studies have reported premenopausal oophorectomy is associated with an increased risk of 
coronary heart disease (CHD), 
12, 13, 85, 87
 with an up to 3% absolute increase in mortality from CHD 
described in women who have early surgical menopause and do not take HRT.
12
 This is in keeping 
with data suggesting that oestrogens have a cardio-protective effect before menopause, and that 
10 
 
reduction of this protection increases the risk of cardiovascular disease. Although an increased risk 




Metabolic syndrome (MetS) has multiple definitions. Key metabolic abnormalities include glucose 
intolerance, insulin resistance, central obesity, dyslipidaemia and hypertension.
89
 In a European 
prospective cohort study, Hu et al. followed 6156 men and 5356 women aged 30–89 years for a 
median of 8.8 years.
90
 Among women, MetS implied an increased risk of death from all causes (HR 
1.38, 95% CI 1.02-1.87) and of death from CVD (HR 2.78, 95% CI 1.57-4.94).
90
 Postmenopausal status has 
been found to be associated with a 60% increased risk of MetS, after adjusting for age, BMI, income 
and physical inactivity.
91
 Data are scarce regarding the association between surgical menopause and 
MetS. An association between premenopausal oophorectomy performed for benign pathology in 
women at population level risk of OC and MetS was demonstrated by Dørum et al.
92
 They found that 
patients with bilateral oophorectomy before 50 years of age (n= 263) had a higher prevalence of 





Data on CHD following premenopausal oophorectomy in BRCA carriers is limited (table-2). A 
Norwegian case-control study by Michelsen et al compared CHD risk profile (total cholesterol, HDL 
cholesterol, blood pressure, BMI, waist circumference) and Framingham risk score of cases (326 
BRCA carriers and women with a strong FH of OC who have undergone RRSO) and age matched 
controls (1630 women at population level risk of OC who had not undergone oophorectomy). 
Baseline cardiovascular morbidity did not differ significantly between cases and controls in terms of 
prevalence of angina, myocardial infarction, stroke, diabetes mellitus or smoking. Results show cases 
had a statistically significantly improved CHD risk profile (lower total cholesterol level, higher HDL 
cholesterol level, lower systolic blood pressure, lower BMI) and lower Framingham total point score 
11 
 
than controls following adjustment for personal history of cancer, education, employment status, 
cohabitation status, HRT use and level of physical activity. These findings linking RRSO with a 
favourable CHD profile must be interpreted with caution due to the small sample size and because 
the comparator group was made up of women at general population risk of OC. Positive health 
seeking behaviour amongst BRCA carriers has been documented in the literature
93
 which may have 
resulted in an improved CHD profile (akin to a healthy volunteer effect) thereby confounding the 
results.  
 
In a prospective cohort study, Cohen et al (n=226) found no statistically significant difference in 
hypertension, diabetes mellitus, hypercholesterolaemia, CHD or MI in BRCA carriers undergoing pre 
or post-menopausal RRSO.
80
 However HRT use in pre-menopasusal women in that study was only 
8%. Advancing age is an independent risk factor for cardiovascular disease
94
 and in this study may be 
a confounder as there was a fifteen year difference between the mean ages of women undergoing 
pre and post-menopausal RRSO (42 vs 57 years).
80
 Also, there were no baseline measurements for 




Michelsen et al concluded that BRCA carriers undergoing RRSO had a more favourable CHD profile 
than controls (women at population level risk of OC who had not undergone oophorectomy),
95
 
women undergoing RRSO were significantly more likely to develop MetS (OR 2.12 95%CI 1.26-3.57, 
P=0.005).
96
 The suggested explanation by the authors is the omission of central obesity when 
evaluating CHD (but included when evaluating MetS) resulted in a more favourable CHD profile in 









There are no data on neurological function post RRSO/RRESDO in BRCA carriers. However there is 
data from women at general population level risk of OC. The Mayo Clinic Cohort Study of 
Oophorectomy and Aging included women who underwent pre-menopausal oophorectomy 
(n=2390) and a group of referent women (n=2390) who did not undergo oophorectomy. Both groups 
were followed up (median 29.5 years) with the same combination of active and passive methods 
(direct or proxy interviews, medical records in a records-linkage system, death certificates).
9-11
 Data 
show a statistically significant increased risk of dementia in women undergoing bilateral 
oophorectomy <48 years who do not receive E-HRT until the age of 50 (HR 1.89, 95%CI 1.27–2.83, 
p=0.002).
9
 In women who undergo bilateral oophorectomy <48 years but who do receive E-HRT, 
there is no increased risk of dementia (HR 0.79, 95%CI 0.25–2.54, p=0.69).
9
 In the same cohort, there 
is a non-statistically significant increase in the risk of parkinsonism and Parkinson’s disease (PD) in 
women undergoing pre-menopausal bilateral oophorectomy <48 years (HR 2.00, 95%CI 0.97–4.15, 
p=0.06).
10
 However, again in this same cohort study, women who underwent bilateral 
oophorectomy <45 years have been found to have an increased all-cause mortality (HR 1·67, 95%CI 
1·16–2·40, p=0·006) as well as mortality specifically associated with neurologic and psychiatric 
disorders (HR 6·28, 95%CI 1·83–21·5, p=0·003).
11
 These findings may suggest that the HRs for 
parkinsonism/PD could be underestimated if the women who died were at increased risk of 
parkinsonism/PD (selective censoring). However PD findings from the Mayo Clinic Cohort study are 
in keeping with other studies including the Nurses’ Health Study (n= 77,713) which have shown that 




Hormone replacement therapy safety and uptake 
13 
 
Several observational studies have evaluated effect of HRT on BC risk in BRCA carriers (table-3).
99-105
 
Mean duration of HRT use reported varies from 3.6–7.6 years.
99-105
  Short term HRT use following 
RRSO in BRCA1/BRCA2 carriers has not been shown to significantly increase BC risk.
99-101, 103-105
 
However sample sizes of these studies are small, follow up short, there is a paucity of data amongst 
HRT use in BRCA2 carriers and there are no RCT data.  
 
Authors of the Women’s Health Initiative (WHI) Randomized Trials reported an increased risk of 
developing BC amongst post-menopausal women aged 50-79 years at population level risk of OC in 
the E+P (oestrogen and progestogen) HRT arm of the trial (HR 1.24, 95%CI 1.01-1.53), and a non-
significant reduction in risk among women in the E-HRT group (HR 0.79, 95%CI 0.61-1.02).
106
 The 
Million Women Study (MWS – observational prospective cohort) reported a significantly increased 
BC risk in post-menopausal women aged 50-64 at population level risk of OC in women using E-HRT 
(RR 1.30, 95%CI 1.21-1.40, p<0.0001), and E+P-HRT (RR 2.00, 95%CI 1.88-2.12, p<0.0001).
107
 
However these results are not generalizable to BRCA carriers who are a younger cohort of women 
undergoing premature/surgical menopause as a result of RRSO and have a different (higher) 
inherent BC risk profile. 
 
Data in BRCA carriers have not shown a significant difference in BC risk between E-alone and E+P 
preparations.
100, 103, 104
 A recent multi-centre prospective cohort study (n=872) has shown that 
progesterone containing HRT (E+P HRT/P-HRT) use following RRSO in BRCA1 carriers <45 years, 
resulted in a non-significant increase in BC for each year of progesterone containing HRT use (HR 
1.14, 95%CI 0.90-1.46, P=0.28).
102
 However the number of women using progesterone containing 
HRT was small (n=62), menopause status at time of RRSO was not reported, HRT use was 
determined via patient self-administered questionnaires, 10% of the study sample was lost to follow 
up and birth cohort effect was not adjusted for. Overall, results of this study are not enough to 
14 
 
change current clinical practice which is to recommend use of short term HRT until the age of fifty-
one (average age of menopause) in BC unaffected BRCA1/BRCA2 carrier undergoing premenopausal 
RRSO. In women with triple negative BC, HRT may be considered for short-term use following 
premenopausal RRSO on a case-by-case basis, particularly with good prognostic disease following a 
multidisciplinary team review involving breast oncologists and menopause specialists.  
 
There are no data on effects of short-term HRT post RRSO until age of natural menopause on 
endometrial cancer risk in BRCA carriers. However the WHI showed a non-significant decrease in the 




HRT use in BRCA carriers undergoing pre-menopausal RRSO improves discomfort/dyspareunia and 
vaginal dryness but does not improve sexual pleasure, habit, satisfaction or libido.
83, 108-110
 Although 
HRT improves certain symptoms of sexual dysfunction, these symptoms are not improved to pre-
surgical levels.
109, 110
 HRT reduces prevalence and severity of hot flushes following pre-menopausal 
RRSO.
83, 108, 109, 111
 HRT use has also been shown to be protective against bone loss in both pre-
menopausal BRCA carriers following RRSO
83
 as well as women at population level risk of OC
112, 113
 
and is protective against hip and total fractures in the general population.
106
 There is no data on the 
efficacy of HRT in preventing ischaemic heart disease in BRCA carriers undergoing pre-menopausal 
RRSO. However data from observation studies indicate that HRT reduces the incidence of ischemic 
heart disease in women at population level risk undergoing premature menopause.
13, 114, 115
 HRT use 




HRT uptake in BRCA carriers after pre and post-menopausal RRSO is reported to be between 6-82% 
(table-3).
54, 57, 104, 111, 116





 This wide variation and potentially low uptake rates in premenopausal women is 
concerning bearing in mind that HRT mitigates the risks of heart disease, osteoporosis, 
neurocognitive decline, vasomotor symptoms and sexual dysfunction in BRCA carriers undergoing 
premenopausal RRSO.  
 
For BRCA carriers undergoing post-menopausal RRSO, HRT uptake is between 0-10%.
80, 110
 There is 
limited data from a case-control studies by Eisen et al (OR 0.68, 95%CI 0.37-1.27, p=0.22) and 
Kotsopoulos et al (OR 0.72, 95%CI 0.44–1.18, p=0.20)
103
 indicating that HRT use following natural 
menopause does not increase the risk of BC. However sample size for these studies were small and 
there was no subgroup analysis performed on the effect of type or preparation of HRT on BC risk. 
Clinicians must be cautious in using systemic HRT in BRCA carriers who have reached natural 
menopause. This is not routinely recommended given paucity and limitations of data in BRCA 
carriers and the findings of the WHI and MWS studies which could potentially impact older BRCA 
carriers who have reached natural menopause. 
 
SUMMARY 
Acceptability of targeted surgical prevention of OC is a multifaceted, fluid and dynamic concept that 
evolves with time and is informed and influenced by counselling received from clinicians on health 
outcomes following surgery and the safety of HRT. RRSO remains gold standard for preventing OC in 
BRCA carriers with uptake being higher in BRCA1 carriers, Caucasians, women who have completed 
childbearing and women with a personal history of BC. However when performed in premenopausal 
BRCA carriers it increases risk of osteoporosis/osteopenia, CHD and neurocognitive decline (though 
BRCA specific data on CHD and neurocognitive impact are limited). Use of HRT until natural 
menopause mitigates risks and there is data supporting safety of short term HRT use in BRCA carriers 
16 
 
without a personal history of receptor positive BC. However despite this, HRT uptake in women 
undergoing premenopausal RRSO remains low highlighting a pressing need for greater education of 
health professionals on safety of HRT which will in turn improve the accuracy of counselling received 
by BRCA carriers. Acceptance of the central role of the fallopian tube in etiopathogenesis of OC 
together with health consequences of premature menopause associated with oophorectomy has led 
to RRESDO being proposed as a two-step surgical alternative for pre-menopausal women who have 
completed their family but decline or wish to delay oophorectomy. Due to unknown implications of 
RRESDO on long term health, extent of OC risk reduction and concerns over attrition, it is 
recommended that it is only offered within the context of a research trial. 
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• Risk reducing salpingo-oophorectomy is the gold standard for ovarian cancer prevention in 
BRCA1 and BRCA2 carriers. It has high acceptability, though a wide range of uptake rates are 
reported in the literature. 
• Risk reducing early salpingectomy and delayed oophorectomy is a surgical alternative 
available solely within the context of a research trial for pre-menopausal women 
declining/wishing to delay oophorectomy. 
• Hormone replacement therapy is recommended following premenopausal oophorectomy 
until the age of fifty-one in women without a personal history of breast cancer. It may be 
considered in receptor negative breast cancer on a case by case basis. 
• Hormone replacement therapy minimises the detrimental consequences of premature 
menopause. 
RESEARCH AGENDA 
• Factors affecting the uptake of postmenopausal risk reducing salpingo-oophorectomy in 
BRCA1 and BRCA2 carriers. 
• Impact of premenopausal RRSO on CHD and neurocognitive function in BRCA carriers 
• Hormone replacement therapy and risk of breast cancer in breast cancer unaffected BRCA2 
carriers undergoing pre-menopausal salpingo-oophorectomy. 
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Table-1: Studies reporting uptake of surgical prevention in BRCA carriers 
Study Country Study design Sample 
size (n) 
Population Type of risk 
reducing 
surgery 
Study findings  Time from 
ascertainment of 
carrier status to 
RRS 





Australia Prospective cohort 266 BRCA1/BRCA2 
carriers 
RRSO Uptake overall: 17.3% 3.73 years (mean) 22/24 
Beattie, 2009
2
  US Retrospective cohort 272 BRCA1/BRCA2 
carriers 







 US Prospective cohort 26 BRCA1 carriers RRSO Uptake overall: 46% (12/26) 







US Retrospective cohort 88 BRCA1/BRCA2 
carriers 









Prospective cohort 1499 BRCA1/BRCA2 
carriers  
RRSO BRCA1 <50 years 86% 
BRCA1 >50 years 13% 
BRCA2 <50 years 71% 




 US Retrospective cohort ? BRCA1/BRCA2 
carriers  
RRSO Black 28% (32/ 
Hispanic 91% (11/ 






Italy Retrospective cohort  79 BRCA1/BRCA2 
carriers 





 UK Prospective cohort 211 BRCA1/BRCA2 
carriers 
RRSO Overall uptake: 45% (96/211) 
Uptake by mutation status: BRCA1 52% (43/211), 
BRCA2 28% (29/211) 
Uptake by age BRCA1/BRCA2: <35 years 12% 
(8/67), 35-45 years 60% (50/84), >45 years 28% 
(14/50) 









Prospective cohort 4649 BRCA1/BRCA2 
carriers 
RRSO Uptake in Jewish women: 54% (522/969) 







US Retrospective cohort 87 BRCA1/BRCA2 
carriers 





US, UK, Austria Prospective cohort 537 BRCA1/BRCA2 
carriers 
RRSO BRCA1 42% (143/339) 
BRCA2 38% (76/198) 
BRCA1 0.9 years 
(mean) 





 US Retrospective cohort 305 BRCA1/BRCA2 
carriers 
RRSO Overall uptake 74% (225/305) 
Uptake by BRCA status: BRCA1 76% (130/170), 








Canada Retrospective cohort 885 BRCA1/BRCA2 
carriers 
RRSO BRCA1: 64.7.% 
BRCA2: 62.2% 





Netherlands Retrospective cohort 580 BRCA1/BRCA2 
carriers 







US Prospective cohort 204 BRCA1/BRCA2 
carriers 





 US Retrospective cohort 170 BRCA1/BRCA2 
carriers 
RRSO Uptake 58% (98/170) 0.3 years (mean) 22/24 
Kim, 2016
17
 South Korea Retrospective cohort 42 BRCA1/BRCA2 
carriers 












RRSO  Considered RRSO before genetic result 31%; 
considered RRSO after genetic result 94% 
Overall actual uptake 78% 







Hong Kong Retrospective cohort 28 BRCA1/BRCA2 
carriers 





Israel Prospective cohort 179 BRCA1/BRCA2 
carriers 





US Prospective cohort 39 BRCA1/BRCA2 
carriers 





Netherlands Retrospective cohort 26 BRCA1/BRCA2 
carriers 





Netherlands Retrospective cohort  369 BRCA1/BRCA2 
carriers or at 
increased risk 
because of FH 
of OC 





 US, Australia Prospective cohort 2287 BRCA1/BRCA2 
carriers  or 
strong FH of OC 







UK Prospective cohort 1133 BRCA1/BRCA2 
(290) carriers  
and UMS 
women (873) 
RRSO Uptake 55% in BRCA carriers  
over 5 years 
 
5 years (mean) 16/16 










Canada Retrospective cohort 56 BRCA1/BRCA2 
carriers 





Canada Retrospective cohort 672 BRCA1/BRCA2 
carriers 





10 countries* Prospective cohort 6223 BRCA1/BRCA2 
carriers 
RRSO Uptake overall:  64.7% (4023/6223) 
BRCA1: 62.8% 
BRCA2: 69.7% 





US prospective, cohort, 
pilot study 












Australia Retrospective cohort 276 BRCA1/BRCA2 
carriers 
RRSO Uptake: 57% (157/276) 
Uptake by mutation status: BRCA1 63% (83/142), 







Australia Prospective cohort 70 BRCA1/BRCA2 
carriers 
RRSO Uptake overall: 29% 3 years 21/24 
Ray, 2005
33
 US Prospective cross-
sectional 
62 BRCA1/BRCA2 
carriers  or 
strong FH of OC 
RRSO Intended uptake: 16% (9/58) 






France Prospective cohort 101 BRCA1/BRCA2 
carriers 





US Retrospective cohort 100 BRCA1/BRCA2 
carriers 
RRSO Uptake 65% (65/100) 
 
5.3 years (mean) 15/16 
Sidon, 2012
36
 UK Retrospective cohort 732 BRCA1/BRCA2 
carriers 
RRSO BRCA1: 54.5% 
BRCA2: 45.5% 
5 years 22/24 
Singh, 2013
37
 US Retrospective cohort 136 BRCA1/BRCA2 
carriers 
RRSO Uptake overall 52% Range 1-11 years 20/24 
Skytte, 2010
38
 Denmark Retrospective cohort 306 BRCA1/BRCA2 
carriers 
RRSO Uptake 75% 10 years 15/16 
Tiller, 2002
39
 Australia Prospective cohort 83 BRCA1/BRCA2 
carriers or at 
increased risk 
because of FH 
of OC 
RRSO Expressed intention to undergo RRSO at baseline:  
24% (20/83) would opt for RRSO, 29% (24/83) 
would decline RRSO, 47% (39/83) unsure; 





 US Retrospective cohort 132 BRCA1/BRCA2 
carriers 





US Retrospective cohort 182 BRCA1/BRCA2 
carriers  or 
RRSO Uptake 34% (62/182) 
 
NR 21/24 
strong FH of OC 
NR – not reported, RRSO – risk reducing salpingo-oophorectomy, RRESDO – risk reducing early salpingectomy with delayed oophorectomy, OC – ovarian cancer, UMS- unknown mutation 
status 

















Table-2: Studies reporting bone and cardiovascular health following surgical prevention in BRCA carriers 
 
Studies Country Study design Sample 
size (n) 
Population Type of risk 
reducing 
surgery 




 UK Retrospective 
cohort 
119 BRCA1/BRCA2 
carriers  or 









 US Prospective 
cohort 
51 BRCA1/BRCA2 
carriers   
RRSO Osteoperosis; 
ostepenia 
Osteopenia: 23% (7/31) 















Pre-menopausal RRSO osteopenia: 61% (54/88); 
post-menopausal RRSO osteopenia: 52% (33/64) 
Pre-menopausal RRSO osteoperosis: 9% (8/88); 
post-menopausal RRSO osteoperosis: 20% 
(13/64) 
Pre-menopausal RRSO diabetes mellitus: 1% 
(1/88); post-menopausal RRSO diabetes mellitus: 
4% (3/64) 
Pre-menopausal RRSO hypercholesterloaemia: 
15% (21/88); post-menopausal RRSO 
hypercholesterolaemia: 18% (15/64) 
Pre-menopausal RRSO CAD/MI: 1% (2/88); post-





 Netherlands Prospective 
cohort 
211 BRCA1/BRCA2 
carriers  or 




osteopenia: 42% (89/211) 
osteoporosis: 6% (13/211) 
Women with RRSO at premenopausal age did 
not have lower BMD and higher fracture 
incidences compared to an age-matched 
population 
5 years 20/24 
Fakkert, 2017
46
 Netherlands Prospective 
cohort 
211 BRCA1/BRCA2 
carriers  or 
strong FH of 
OC 
RRSO Fracture risk increase in bone turnover measured after RRSO 
which are linked to future fracture risk 
5 years 20/24 
Garcia, 2015
47
 US Retrospective 
cohort 
225 BRCA1/BRCA2 
carriers   
RRSO Osteoporosis; 
osteopenia; fractures 
osteopenia 55.6%  
osteoporosis 12.1% 
Fracture post RRSO: 4% (10/225). 
RRSO in BRCA carriers was not found to be 
















carriers  or 





















carriers  or 





RRSO Metabolic syndrome RRSO significantly associated with metabolic 
syndrome according to the 2005 National 
Cholesterol Education Program Adult Treatment 
Panel III criteria (OR 2.46 [95% CI 1.63-3.73]) and 
according to the International Diabetes 














carriers  or 





RRSO CHD Except for a wider waist circumference, cases 
had a more favourable CHD risk profile including 
more physical activity, lower levels of total 
cholesterol (5.8 vs 6.3 mmol/L), higher levels of 
high-density lipoprotein cholesterol (1.7 vs 1.5 
mmol/L), lower systolic blood pressure (128 vs 
139 mmHg), and lower BMI (25 vs 27 kg/m
2
) 
compared with controls 
Cases had a lower mean (SD) Framingham total 
score compared to the controls (12.9 [5.1] vs 






 US Prospective 
cohort 
238 BRCA1/BRCA2 
carriers   
RRSO Osteoporosis Premenopausal RRSO: 13% 
Postmenopausal RRSO: 17% 
NR 21/24 
NR – not reported, RRSO – risk reducing salpingo-oophorectomy, RRESDO – risk reducing early salpingectomy with delayed oophorectomy, OC – ovarian cancer, CHD – coronary heart disease, 





Table-3: Studies reporting hormone replacement therapy uptake, safety and efficacy in BRCA carriers  
Studies Country Study design Sample 
size (n) 
Population Type of risk 
reducing 
surgery 




 UK Retrospective 
cohort 
119 BRCA1/BRCA2 
carriers  or 
strong FH of 
OC 
RRSO HRT efficacy Less sexual dysfunction in HRT use vs no HRT use 
group (p=0.09) 
Fewer vasomotor symptoms in HRT use group vs 
past use or never use (p= 0.03) 
Reduced incidence of osteoporosis/osteopenia 
on DEXA scans with HRT use vs no use 









RRSO HRT uptake  Pre-menopausal HRT uptake: 8% (11/144); post-








RRSO HRT uptake  HRT uptake post RRSO 21% (9/42) NR 11/16 
Eisen, 2008
52
 Canada Retrospective 
case-control 
236 cases 







N/A HRT safety OR for breast cancer associated with ever use of 
HRT compared with never use was 0.58 (95% CI = 
0.35 to 0.96; P = .03). 
4 years 21/24 
Finch, 2011
53




RRSO HRT uptake, HRT 
efficacy 
 
HRT uptake: pre-menopausal RRSO 39% (29/75), 
postmenopausal RRSO 10% (4/39)  
 
Less sexual dysfunction in HRT use vs no HRT use 
group (p=0.015) 
Fewer vasomotor symptoms in HRT use vs no 
HRT use group (p=0.0003) 
Greater QoL in HRT use vs no use group as 
measured by the MENQOL questionnaire 
1 year 22/24 
Finch, 2013
54




RRSO HRT uptake HRT uptake 30% (29/96) 
 
1 year 21/24 
Johansen, 2016
55








carriers  or 





RRSO HRT uptake HRT uptake 44% (119/294) NR 21/24 
Kotsopoulos, 2016
56







carriers women who ever used HRT to those who never 
used HRT was 0.80 (95 % CI 0.55–1.16; P = 0.24) 
Kotsopoulos, 2018
57




N/A HRT safety HR 0.97 (95%CI 0.62-1.52; P=0.89) for ever use of 
any type of HRT vs no use 
HR 0.73 (95%CI 0.41-1.32; p=0.30) for ever use of 
E-HRT vs no use 
HR 1.31 (0.66-2.57; P=0.44) for ever use of E+P 






 Netherlands Retrospective 
cohort  
164 BRCA1/BRCA2 
carriers or at 
increased risk 
because of FH 
of OC 
RRSO HRT uptake; HRT 
efficacy 
Pre-menopausal HRT uptake post RRSO 38% 
(63/164) 
RRSO HRT users group reported significantly 
fewer symptoms overall than RRSO HRT 
nonusers group (P<0.05) 
RRSO HRT users and RRSO HRT non users groups 
reported comparable levels of sexual 
functioning. Compared with the GS group, the 
RRSO HRT users group reported significantly 















HRT uptake (RRSO 
arm only) 






















RRSO HRT safety HRT of any type after RRSO did not significantly 
alter the reduction in breast cancer risk 
associated with RRSO (HR 0.37; 95% CI 0.14 -
0.96). 
3.6 years 22/24 
Tiller, 2002
39
 Australia Prospective 
cohort 
83 BRCA1/BRCA2 
carriers or at 
increased risk 
because of FH 
of OC 
RRSO HRT uptake HRT uptake post RRSO 82% 3 years 24/24 
Tucker, 2016
60
 Australia Cross-sectional 119 BRCA1/BRCA2 RRSO HRT efficacy The risk of sexual dysfunction in those NR 20/24 
carriers  or 
strong FH of 
OC 
participants using topical vaginal oestrogen was 
84% less than those not using it. 
Greater QoL with HRT use vs no use (p=0.010) 
Vermeulen, 2017
61




RRSO HRT uptake Pre-menopausal HRT uptake: 47% (27/57) 9 months 22/24 
NR – not reported, RRSO – risk reducing salpingo-oophorectomy, RRESDO – risk reducing early salpingectomy with delayed oophorectomy, OC – ovarian cancer, QoL – quality of life, HRT – 
hormone replacement therapy, DEXA - dual-energy X-ray absorptiometry
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HIGHLIGHTS 
• Acceptability of surgical prevention of ovarian-cancer in BRCA-carriers is a dynamic concept.  
• Acceptability is influenced by counselling on health outcomes after surgery and HRT safety.  
• Premenopausal oophorectomy increases risk of osteoporosis, heart-disease, neurocognitive-
decline.  
• HRT use until natural-menopause mitigates risks and data supports safety of short term use 
in BRCA-carriers. 
